Hengrui Medicine adds key drugs to national reimbursement list

Jiangsu Hengrui Medicine confirmed that multiple products have been added to the National Medical Insurance Drug Catalog (2025) following negotiations with regulatory bodies. The newly included drugs cover oncology, autoimmune diseases, and metabolic disorders, and are expected to facilitate their sale.

Key newly added drugs include injectable reksertuzumab, famitinib malate capsules, and furonafizumab injection. Additionally, new indications for existing drugs like camrelizumab injection and fluzoparib capsules were approved. Other drugs such as pyrrolinib maleate tablets and eltrombopag olamine tablets had their listings successfully renewed.

Based on 2024 figures, total sales of these listed drugs amounted to CNY 8.66 bn, with 2025 first-quarter sales reaching CNY 7.554 bn. The 2025 National Medical Insurance Drug Catalog officially commences on January 1, 2026. The company noted that the impact on its operating performance is currently unquantifiable.